{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:03:47Z","timestamp":1792098227713,"version":"4.4.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T00:00:00Z","timestamp":1392940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0089454","type":"journal-article","created":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T17:14:56Z","timestamp":1393002896000},"page":"e89454","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":125,"title":["Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer\u2019s Disease"],"prefix":"10.1371","volume":"9","author":[{"given":"Soumee","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Haertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Maelicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Montag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,2,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics","volume":"10","author":"E Karran","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrn1495","article-title":"Strategies for disease modification in Alzheimer\u2019s disease","volume":"5","author":"M Citron","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1073\/pnas.0811698106","article-title":"Oligomeric amyloid \u03b2 associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques","volume":"106","author":"RM Koffie","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1523\/JNEUROSCI.1879-05.2005","article-title":"Dendritic spine abnormalities in APP transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy","volume":"25","author":"TL Spires","year":"2005","journal-title":"J Neurosci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.96.9.5274","article-title":"Plaque-induced neurite abnormalities: Implications for disruption of neural networks in Alzheimer\u2019s disease","volume":"96","author":"RB Knowles","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/nm.1872","article-title":"Glutaminyl cyclase inhibition attenuates pyroglutamate A\u03b2 and Alzheimer\u2019s disease-like pathology in vivo","volume":"14","author":"S Schilling","year":"2008","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","article-title":"Alzheimer\u2019s disease: strategies for disease modification","volume":"9","author":"M Citron","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","article-title":"Combination therapy for Alzheimer\u2019s disease","volume":"28","author":"L Patel","year":"2011","journal-title":"Drugs Aging"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0006-3223(00)01109-4","article-title":"Allosteric Sensitization of Nicotinic Receptors by Galantamine, a New Treatment Strategy for Alzheimer\u2019s Disease","volume":"49","author":"A Maelicke","year":"2001","journal-title":"Biol Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1124\/mol.51.5.776","article-title":"Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y","volume":"51","author":"X Peng","year":"1997","journal-title":"Mol Pharmacol"},{"key":"ref11","first-page":"216","article-title":"CNS nicotine receptors. Possible therapeutic targets in neurodegenerative disorders","volume":"2","author":"JA Court","year":"1994","journal-title":"CNS Drugs"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0006-8993(98)00138-3","article-title":"Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity","volume":"792","author":"T Kihara","year":"1998","journal-title":"Brain Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/13543784.16.12.1987","article-title":"An update on the pharmacology of galantamine","volume":"16","author":"M Villarroya","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cbi.2006.11.008","article-title":"Nicotinic component of galantamine in the regulation of amyloid precursor protein processing","volume":"165","author":"SC Lenzken","year":"2007","journal-title":"Chem Biol Interact"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jns.2009.01.024","article-title":"Galantamine inhibits beta-amyloid aggregation and cytotoxicity","volume":"280","author":"B Matharu","year":"2009","journal-title":"J Neurol Sci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"40180","DOI":"10.1074\/jbc.M110.142356","article-title":"Galantamine-induced Amyloid-\u03b2 Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors","volume":"285","author":"K Takata","year":"2010","journal-title":"J Biol Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/NDT.S24196","article-title":"Galantamine treatment in Alzheimer\u2019s disease: response and long-term outcome in a routine clinical setting","volume":"7","author":"\u00c5K Wallin","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0404.2011.01525.x","article-title":"Galantamine and behavior in Alzheimer disease: analysis of four trials","volume":"124","author":"S Kavanagh","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JAD-2010-101290","article-title":"Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer\u2019s disease patients","volume":"24","author":"C Keller","year":"2011","journal-title":"J Alz Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal \u03b2-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer\u2019s Disease Mutations: Potential Factors in Amyloid Plaque Formation","volume":"26","author":"H Oakley","year":"2006","journal-title":"J Neurosci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2006.12.008","article-title":"BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP\/PS1 transgenic mice","volume":"26","author":"M Ohno","year":"2007","journal-title":"Neurobiol Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1096\/fj.12-217497","article-title":"A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer\u2019s disease phenotypes in model mice","volume":"27","author":"V Shukla","year":"2013","journal-title":"FASEB J"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"41517","DOI":"10.1074\/jbc.M110.178707","article-title":"Identification of low molecular weight pyroglutamate A\u03b2 oligomers in Alzheimer\u2019s disease: a novel tool for therapy and diagnosis","volume":"285","author":"O Wirths","year":"2010","journal-title":"J Biol Chem"},{"key":"ref24","first-page":"e29","article-title":"Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A\u03b2 aggregation in the 5XFAD mouse model of Alzheimer\u2019s disease","volume":"196","author":"S Jawhar","year":"2012","journal-title":"Neurobiol Aging 33"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1128\/MCB.22.22.7967-7981.2002","article-title":"Misguided axonal projections, NCAM180 mRNA upregulation, and altered behavior in mice deficient for the Close Homolog of L1 (CHL1)","volume":"22","author":"M Montag-Sallaz","year":"2002","journal-title":"Mol Cell Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1034\/j.1601-183X.2003.00003.x","article-title":"Severe cognitive and motor coordination deficits in Tenascin-R-deficient mice","volume":"2","author":"M Montag-Sallaz","year":"2003","journal-title":"Genes Brain Behav"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Wishaw IQ, Haun F, Kolb B (1999) Analysis of behavior in laboratory rodents. In : Windhorst, U. & Johansson, H., eds. Modern Techniques in Neurosci Berlin Springer 1243\u20131275.","DOI":"10.1007\/978-3-642-58552-4_44"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s003359900551","article-title":"Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment","volume":"8","author":"DC Rogers","year":"1997","journal-title":"Mamm Genome"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1101\/lm.53403","article-title":"Learning-induced arg 3.1 expression in the mouse brain","volume":"10","author":"M Montag-Sallaz","year":"2003","journal-title":"Learn Mem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1523\/JNEUROSCI.2693-05.2005","article-title":"Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"25","author":"TA Comery","year":"2005","journal-title":"J. Neurosci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1073\/pnas.0600948103","article-title":"Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer\u2019s disease","volume":"103","author":"JS Jacobsen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/002215540205000403","article-title":"Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections","volume":"50","author":"A Sun","year":"2002","journal-title":"J Histochem Cytochem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2000.tb06915.x","article-title":"Pathogenic mechanisms of Alzheimer\u2019s disease analyzed in the APP23 transgenic mouse model","volume":"920","author":"C Sturchler-Pierrat","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","article-title":"Enhanced Neurofbrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP","volume":"293","author":"J Lewis","year":"2001","journal-title":"Science"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0002-9440(10)64064-3","article-title":"Augmented Senile Plaque Load in Aged Female b-Amyloid Precursor Protein-Transgenic Mice","volume":"158","author":"MJ Callahan","year":"2001","journal-title":"Am J Pathol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF01923594","article-title":"An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer\u2019s disease","volume":"48","author":"R Guntern","year":"1992","journal-title":"Experientia"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1038\/ncomms3734","article-title":"Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-\u03b2 secretion via deregulated lysosomal exocytosis","volume":"4","author":"I Annunziata","year":"2013","journal-title":"Nat Commun"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuroimage.2010.08.033","article-title":"Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain","volume":"54","author":"TM Wengenack","year":"2011","journal-title":"Neuroimage"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1523\/JNEUROSCI.16-14-04491.1996","article-title":"Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer\u2019s Disease","volume":"16","author":"T Gomez-Isla","year":"1996","journal-title":"J Neurosci"},{"key":"ref40","first-page":"2","article-title":"5XFAD Tg mice that express five FAD mutations have high-cerebral a\u03b242 levels, rapid amyloid deposition, and intraneuronal a\u03b2","volume":"587","author":"RJ Vassar","year":"2005","journal-title":"Soc Neurosci Abstr"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12035-012-8281-x","article-title":"Alzheimer\u2019s disease, Oestrogen and mitochondria: an ambiguous relationship","volume":"46","author":"A Grimm","year":"2012","journal-title":"Mol Neurobiol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00702-006-0580-9","article-title":"Gender dependent APP processing in a transgenic mouse model of Alzheimer\u2019s disease","volume":"114","author":"S Schaeffer","year":"2007","journal-title":"J Neural Transm"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1017\/S0029665112002753","article-title":"Weight loss and Alzheimer\u2019s disease: temporal and aetiologic connections","volume":"72","author":"G Sergi","year":"2013","journal-title":"Proc Nutri Soc"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/alzrt182","article-title":"Comprehensive behavioral characterization of an APP\/PS-1 double knock-in mouse model of Alzheimer\u2019s disease","volume":"5","author":"SJ Webster","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10048-009-0201-5","article-title":"COL25A1 triggers and promotes Alzheimer\u2019s disease-like pathology in vivo","volume":"11","author":"Y Tong","year":"2010","journal-title":"Neurogenet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.neubiorev.2012.02.011","article-title":"APP transgenic mice for modelling behavioral and psychological symptoms of dementia (BPSD)","volume":"36","author":"R Lalonde","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1460-9568.2005.04551.x","article-title":"Temporal memory deficits in Alzheimer\u2019s mouse models: rescue by genetic deletion of BACE1","volume":"23","author":"M Ohno","year":"2006","journal-title":"Eur Jour Neurosci"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.nbd.2008.10.006","article-title":"Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model","volume":"33","author":"R Kimura","year":"2009","journal-title":"Neurobiol Dis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1176\/appi.ajp.158.8.1319","article-title":"Sensory Gating Deficit Expressed by a Disturbed Suppression of the P50 Event-Related Potential in Patients With Alzheimer\u2019s Disease","volume":"158","author":"F Jessen","year":"2001","journal-title":"Am J Psychiatry"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.wnp.0000218991.99714.ee","article-title":"Sensory gating deficit assessed by P50\/Pb middle latency event related potential in Alzheimer\u2019s disease","volume":"23","author":"I Cancelli","year":"2006","journal-title":"J Clin Neurophys"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bbr.2012.05.007","article-title":"Sensorimotor gating and memory deficits in an APP\/PS1 double transgenic mouse model of Alzheimer\u2019s disease","volume":"233","author":"H Wang","year":"2012","journal-title":"Beh Brain Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/17425251003592137","article-title":"Galantamine for Alzheimer\u2019s disease. Expert Opin","volume":"6","author":"D Prvulovic","year":"2010","journal-title":"Drug Metab Toxicol"},{"key":"ref53","first-page":"1","article-title":"Galantamine-ER for the treatment of mild-to-moderate Alzheimer\u2019s disease","volume":"5","author":"B Seltzer","year":"2010","journal-title":"Clin Interv Aging"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejmech.2013.09.050","article-title":"Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection","volume":"70","author":"M Singh","year":"2013","journal-title":"Eur J Med Chem"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bmcl.2012.10.111","article-title":"Investigating the binding interactions of galantamine with b-amyloid peptide","volume":"23","author":"PPN Rao","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1124\/jpet.105.098566","article-title":"Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice","volume":"317","author":"C Unger","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice","volume":"76","author":"RB Demattos","year":"2012","journal-title":"Neuron"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ana.22333","article-title":"Amyloid-\u03b2 associated cortical thinning in clinically normal elderly","volume":"69","author":"JA Becker","year":"2011","journal-title":"Ann Neurol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1212\/WNL.0b013e318246d67a","article-title":"Accelerated cortical atrophy in cognitively normal elderly with high \u03b2-amyloid deposition","volume":"78","author":"G Ch\u00e9telat","year":"2012","journal-title":"Neurol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.neurobiolaging.2011.04.012","article-title":"The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer\u2019s disease","volume":"33","author":"S Kalinin","year":"2012","journal-title":"Neurobiol Aging"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/156720511794604543","article-title":"Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer\u2019s disease","volume":"8","author":"C Li","year":"2011","journal-title":"Curr Alzheimer Res"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-009-9269-5","article-title":"Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy","volume":"40","author":"A Maelicke","year":"2010","journal-title":"J Mol Neurosci"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0089454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T17:43:36Z","timestamp":1588959816000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0089454"}},"subtitle":[],"editor":[{"given":"Thomas","family":"Arendt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,21]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0089454","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,21]]}}}